Friday, September 7th, 2012
Diabetes treatment developer AIMEDICS has announced the first use of the company’s HypoMon product in the UK involving 2 young people with type 1 diabetes who have successfully used it during August 2012.

AIMEDICS has developed a non-invasive sleep alarm system initially for people between 10 and 25 years of age with type I diabetes. Called HypoMon, the system identifies sleep time “hypos” – or dangerously low blood sugar levels – and alerts the patient and carer through a monitor and alarm.

Victor Skladnev, AIMEDICS CEO said: “We are very excited to have our first customers benefiting from the HypoMon in the UK. This is a critical step in AIMEDICS UK sales and marketing strategy to prove the value of the HypoMon to users and healthcare professionals.”

The HypoMon is more accurate, more comfortable and more affordable than anything on the diabetes treatment market. HypoMon assures a safer, more comfortable night’s sleep for all – both patients and carers.

The product has been rigorously trialed at children’s hospitals in Australia, and successfully identifies eight out of ten sleep time hypos.

AIMEDICS will be participating at the Wholesale Investor Sydney Capital Showcase 2012.

Contact Profile

Wholesale Investor

Wholesale Investor is Australia's leading private investment platform showcasing Private, Pre-IPO and Life Sciences ASX Listed Opportunities to over 9200 High Net Worth, Professional and International investors.
Steve Torso, Managing Director, Wholesale Investor
P: 1300 597 595


Diabetes treatment



More Formats

View QR Code